The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
20th Jan 20203:23 pmRNSHolding(s) in Company
13th Jan 20208:37 amRNSHolding(s) in Company
9th Jan 202010:04 amEQSEdison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
9th Jan 20208:43 amRNSHolding(s) in Company
8th Jan 20209:11 amRNSHolding(s) in Company
7th Jan 202010:12 amRNSHolding(s) in Company
7th Jan 20207:00 amRNSSilence Therapeutics Announces Business Update
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20193:31 pmRNSManagement Change
17th Dec 20197:45 amRNSBoard changes
17th Dec 20197:45 amRNSDirector disclosure
27th Nov 20199:14 amRNSAdditional Listing
22nd Nov 20199:23 amRNSAdditional Listing
13th Nov 20192:45 pmRNSHolding(s) in Company
30th Oct 20193:13 pmRNSAdditional Listing
25th Oct 201910:25 amRNSAdditional Listing
14th Oct 201910:40 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHoldings in Company
7th Oct 20197:00 amRNSGrant of share options
4th Oct 20195:21 pmRNSDirector/PDMR Shareholding and Additional Listing
3rd Oct 20193:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20195:09 pmRNSDirector/PDMR Shareholding
1st Oct 20196:06 pmRNSDirector/PDMR Shareholding and Additional Listing
30th Sep 20195:09 pmRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSFirst research milestone for SLN500
20th Sep 20193:19 pmRNSAdditional Listing
16th Sep 20194:46 pmRNSAdditional Listing
12th Sep 20197:00 amRNSInterim results for six months ended 30 June 2019
27th Aug 20198:28 amRNSHolding(s) in Company
21st Aug 201910:14 amRNSAdditional Listing
19th Aug 20193:15 pmRNSAdditional Listing
15th Aug 20197:00 amRNSNotice of Results and R&D day
13th Aug 20197:00 amRNSAdditional Listing
8th Aug 20194:27 pmRNSAdditional Listing
7th Aug 20191:38 pmRNSAdditional Listing
6th Aug 201912:41 pmRNSAdditional Listing
5th Aug 20197:00 amRNSSilence Therapeutics appoints Jørgen Wittendorff
1st Aug 20194:22 pmRNSHolding(s) in Company
31st Jul 20198:19 amRNSHolding(s) in Company
30th Jul 20195:30 pmRNSAdditional Listing
29th Jul 20197:00 amRNSBoard Appointment
26th Jul 20191:33 pmRNSHolding(s) in Company
25th Jul 201912:26 pmRNSHolding(s) in Company
24th Jul 20198:43 amRNSHolding(s) in Company
23rd Jul 201911:27 amRNSAdditional Listing
19th Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jul 20193:13 pmRNSAdditional Listing
18th Jul 201911:46 amRNSMallinckrodt to make equity investment in Silence
18th Jul 201911:45 amRNSSilence collaboration with Mallinckrodt
16th Jul 201911:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.